Gynecologic Cancers

ESMO 2026 put gynecological oncology in the spotlight, with new survival data, phase III trial results and emerging therapies bringing cervical, endometrial and ovarian cancer into focus. The key sessions examined the role of immunotherapy, ADCs and targeted agents across first-line and previously treated settings. The findings included improved PFS with pembrolizumab in dMMR endometrial cancer, OS results from randomized studies and early efficacy data for investigational treatments in recurrent ovarian cancer.

Can advances in antibody-drug conjugate design translate into meaningful survival benefits across more tumor types and earlier treatment settings, without unacceptable toxicity? Having transformed treatment for HER2-positive breast cancer, ADCs are now taking center stage in Madrid, featuring in one-third of the Presidential Symposium late-breaking abstracts. These studies illustrate a shift from established HER2-directed approaches, toward a broader landscape of targets, payloads and clinical applications. In this article, we examine the key trials to watch and the clinical questions they aim to address.

With the European Society for Medical Oncology (ESMO) Congress 2026 fast approaching, attention is turning to Madrid, where the meeting is held from 23–27th October. Whether you are joining onsite or via the virtual platform, the three Presidential Symposia are the sessions not to miss. This year they carry 12 late-breaking abstracts (LBAs) spanning melanoma, lung, genitourinary, gastrointestinal, gynecological and rare cancers. With close to 300 scientific and educational sessions to choose from, we know the programme can feel overwhelming. So we have put together a quick guide to the headline sessions: when and where they run, who is presenting, and links to explore each one in the programme planner, so you can decide which to prioritize.

The European Society for Medical Oncology (ESMO) Congress 2026 promises a compelling program of clinical data, spanning personalized cancer vaccines, next-generation antibody–drug conjugates (ADCs) and novel approaches to targeted therapy and immunotherapy. With several studies already generating excitement following positive topline announcements, all eyes will be on the full results and their potential implications for clinical practice. Below, we highlight the 12 presidential abstracts to watch, the key findings to look out for and the questions these studies could help answer.

Faculty discusses cases of advanced endometrial cancer, reviewing molecular testing, treatment, and toxicity

See who the oncology community selected as the rising stars of 2026!

We often focus on clinical excellence, but spend less time developing broader skills that could help us better lead with purpose and build more fulfilling, impactful careers. In this episode, part of a mini-series in partnership with LEADderm, Dr Jennifer Soung and Denise Mann explore how clinicians can engage with the media to educate, empower and extend their impact beyond the clinic.

At ESGO26 investigators answered some of the field’s most persistent questions: the optimal timing of surgery, chemotherapy scheduling, the promise of immunotherapy in platinum-resistant disease and how molecular profiling can sharpen surgical decision-making. And the results didn't disappoint. Below are four of the most important abstracts from the Late-breaking, Best Oral and Best Three Minutes sessions: ENGOT-ov65/KEYNOTE-B96, RACC, ACR-368-201 and EUGENIE revealed insights that could shift the standard of care. Here’s what you need to know.